These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22950667)

  • 1. Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold.
    Fazekas T; Eickhoff P; Pruckner N; Vollnhofer G; Fischmeister G; Diakos C; Rauch M; Verdianz M; Zoubek A; Gadner H; Lion T
    BMC Complement Altern Med; 2012 Sep; 12():147. PubMed ID: 22950667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial.
    Ludwig M; Enzenhofer E; Schneider S; Rauch M; Bodenteich A; Neumann K; Prieschl-Grassauer E; Grassauer A; Lion T; Mueller CA
    Respir Res; 2013 Nov; 14(1):124. PubMed ID: 24219370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold.
    Eccles R; Meier C; Jawad M; Weinmüllner R; Grassauer A; Prieschl-Grassauer E
    Respir Res; 2010 Aug; 11(1):108. PubMed ID: 20696083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial.
    Eccles R; Winther B; Johnston SL; Robinson P; Trampisch M; Koelsch S
    Respir Res; 2015 Oct; 16():121. PubMed ID: 26438038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials.
    Koenighofer M; Lion T; Bodenteich A; Prieschl-Grassauer E; Grassauer A; Unger H; Mueller CA; Fazekas T
    Multidiscip Respir Med; 2014; 9(1):57. PubMed ID: 25411637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iota-Carrageenan is a potent inhibitor of rhinovirus infection.
    Grassauer A; Weinmuellner R; Meier C; Pretsch A; Prieschl-Grassauer E; Unger H
    Virol J; 2008 Sep; 5():107. PubMed ID: 18817582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial data.
    Hemilä H; Chalker E
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00810. PubMed ID: 34128358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis-ICE-COVID.
    Jessop ZM; Gibson J; Lim JY; Jovic TH; Combellack E; Dobbs TD; Carter K; Hiles S; Islam S; Healy B; Humphreys I; Eccles R; Hutchings HA; Whitaker IS
    Trials; 2022 Sep; 23(1):782. PubMed ID: 36109791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of iota-carrageenan nasal spray in treatment and prevention of the common cold.
    Bichiri D; Rente AR; Jesus Â
    Med Pharm Rep; 2021 Jan; 94(1):28-34. PubMed ID: 33629045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iota-carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell culture.
    Bansal S; Jonsson CB; Taylor SL; Figueroa JM; Dugour AV; Palacios C; Vega JC
    PLoS One; 2021; 16(11):e0259943. PubMed ID: 34797868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a nasal spray containing xylometazoline hydrochloride and iota-carrageenan for the symptomatic relief of nasal congestion caused by rhinitis and sinusitis.
    Graf C; Bernkop-Schnürch A; Egyed A; Koller C; Prieschl-Grassauer E; Morokutti-Kurz M
    Int J Gen Med; 2018; 11():275-283. PubMed ID: 30013382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing upper respiratory tract infections with prophylactic nasal carrageenan: a feasibility study.
    Halley C; Honeywill C; Kang J; Pierse N; Robertson O; Rawlinson W; Stelzer-Braid S; Willink R; Crane J
    Future Microbiol; 2023 Dec; 18():1319-1328. PubMed ID: 37830932
    [No Abstract]   [Full Text] [Related]  

  • 13. Early intervention with ColdZyme mouth spray after self-diagnosis of common cold: A randomized, double-blind, placebo-controlled study.
    Lindberg BF; Nelson I; Ranstam J; Riker DK
    PLoS One; 2023; 18(1):e0279204. PubMed ID: 36652464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Cunningham S; Piedra PA; Martinon-Torres F; Szymanski H; Brackeva B; Dombrecht E; Detalle L; Fleurinck C;
    Lancet Respir Med; 2021 Jan; 9(1):21-32. PubMed ID: 33002427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a fixed combination phytomedicine in the treatment of the common cold (acute viral respiratory tract infection): results of a randomised, double blind, placebo controlled, multicentre study.
    Henneicke-von Zepelin H; Hentschel C; Schnitker J; Kohnen R; Köhler G; Wüstenberg P
    Curr Med Res Opin; 1999; 15(3):214-27. PubMed ID: 10621929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial.
    Castellarnau A; Heery GP; Seta A; Luscombe CA; Kinghorn GR; Button P; McCloud P; Paull JRA
    Sci Rep; 2022 Jun; 12(1):10210. PubMed ID: 35715644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease.
    Figueroa JM; Lombardo ME; Dogliotti A; Flynn LP; Giugliano R; Simonelli G; Valentini R; Ramos A; Romano P; Marcote M; Michelini A; Salvado A; Sykora E; Kniz C; Kobelinsky M; Salzberg DM; Jerusalinsky D; Uchitel O
    Int J Gen Med; 2021; 14():6277-6286. PubMed ID: 34629893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of symptoms and plasma cytokine levels in patients with the common cold treated with zinc acetate. A randomized, double-blind, placebo-controlled trial.
    Prasad AS; Fitzgerald JT; Bao B; Beck FW; Chandrasekar PH
    Ann Intern Med; 2000 Aug; 133(4):245-52. PubMed ID: 10929163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, placebo-controlled study of the safety and efficacy of ipratropium bromide nasal spray versus placebo in patients with the common cold.
    Dockhorn R; Grossman J; Posner M; Zinny M; Tinkleman D
    J Allergy Clin Immunol; 1992 Dec; 90(6 Pt 2):1076-82. PubMed ID: 1460211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers.
    Hayden FG; Turner RB; Gwaltney JM; Chi-Burris K; Gersten M; Hsyu P; Patick AK; Smith GJ; Zalman LS
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3907-16. PubMed ID: 14638501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.